Spyre Therapeutics
SYRE
SYRE
55 hedge funds and large institutions have $22.6M invested in Spyre Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
-11
Holders Change %
-16.67%
% of All Funds
0.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
11
Reduced
14
Closed
15
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$15K
Top Buyers
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$180K |
| 2 |
Millennium Management
New York
|
+$154K |
| 3 |
Two Sigma Advisers
New York
|
+$93.9K |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$39.5K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$28.9K |
Top Sellers
| 1 |
LPC
Lion Point Capital
New York
|
-$1.43M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.24M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$255K |
| 4 |
D.E. Shaw & Co
New York
|
-$241K |
| 5 |
Renaissance Technologies
New York
|
-$174K |
